These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38678948)

  • 1. Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma.
    Huo R; Yang WJ; Liu Y; Liu T; Li T; Wang CY; Pan BS; Wang BL; Guo W
    Phytomedicine; 2024 Jul; 129():155225. PubMed ID: 38678948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic activity of
    Yu H; Lin G; Jiang J; Yao J; Pan Z; Xie H; Bo Z; He Q; Yang J; Chen Z; Li J; Wang Y; Yu Z; Assaraf YG; Chen G
    Gut Microbes; 2024; 16(1):2410474. PubMed ID: 39353096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8
    Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
    J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma.
    Shou JW; Shaw PC
    Phytomedicine; 2023 Jul; 115():154842. PubMed ID: 37148713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis.
    Wen S; He L; Zhong Z; Zhao R; Weng S; Mi H; Liu F
    Front Immunol; 2021; 12():741934. PubMed ID: 34691046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberine Promotes Induction of Immunological Tolerance to an Allograft via Downregulating Memory CD8
    Qiu F; Lu W; Ye S; Liu H; Zeng Q; Huang H; Liang CL; Chen Y; Zheng F; Zhang Q; Lu CJ; Dai Z
    Front Immunol; 2021; 12():646831. PubMed ID: 33643325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.
    Chen L; Zhou S; Qin J; Hu H; Ma H; Liu B; Wang X; Ma J; Ye S; Zhong C; Zhou G; Liang C
    Mol Cancer; 2013 Dec; 12(1):153. PubMed ID: 24304581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
    Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
    Yan Y; Wang L; He J; Liu P; Lv X; Zhang Y; Xu X; Zhang L; Zhang Y
    Biomed Pharmacother; 2017 Apr; 88():395-402. PubMed ID: 28122304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
    Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
    J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal microbiota imbalance resulted by anti-Toxoplasma gondii immune responses aggravate gut and brain injury.
    Chen J; Zhang C; Yang Z; Wu W; Zou W; Xin Z; Zheng S; Liu R; Yang L; Peng H
    Parasit Vectors; 2024 Jul; 17(1):284. PubMed ID: 38956725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yangyin Fuzheng Jiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma by alleviating exhausted T cells.
    Yan F; Wang X; Xie Y; Liu X; Yu L; Wang P; Li T; Wang S; Li W; Yang Z
    Phytomedicine; 2021 Oct; 91():153722. PubMed ID: 34488188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.
    Zhou Y; Fu C; Kong Y; Pan D; Wang Y; Huang S; Li Z; Ning Z; Lu X; Shan S; Xin L
    Anticancer Drugs; 2019 Oct; 30(9):909-916. PubMed ID: 30998512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
    Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
    Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol exerts antitumor effects by downregulating CD8
    Zhang Q; Huang H; Zheng F; Liu H; Qiu F; Chen Y; Liang CL; Dai Z
    Oncoimmunology; 2020 Oct; 9(1):1829346. PubMed ID: 33150044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
    Flecken T; Schmidt N; Hild S; Gostick E; Drognitz O; Zeiser R; Schemmer P; Bruns H; Eiermann T; Price DA; Blum HE; Neumann-Haefelin C; Thimme R
    Hepatology; 2014 Apr; 59(4):1415-26. PubMed ID: 24002931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment.
    Zhang F; Zhou K; Yuan W; Sun K
    Nutr Cancer; 2024; 76(1):63-79. PubMed ID: 37909316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.